Free Trial

Fennec Pharmaceuticals Q3 2023 Earnings Report

Fennec Pharmaceuticals logo
C$9.50 +0.63 (+7.10%)
As of 02/21/2025 03:47 PM Eastern

Fennec Pharmaceuticals EPS Results

Actual EPS
-C$0.09
Consensus EPS
-C$0.15
Beat/Miss
Beat by +C$0.06
One Year Ago EPS
N/A

Fennec Pharmaceuticals Revenue Results

Actual Revenue
$8.74 million
Expected Revenue
$6.94 million
Beat/Miss
Beat by +$1.80 million
YoY Revenue Growth
N/A

Fennec Pharmaceuticals Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Fennec Pharmaceuticals Earnings Headlines

Fennec Pharmaceuticals (FENC) Gets a Buy from Craig-Hallum
Fennec announces three executive appointments
9/9 on TSLA from June to January
Please take a look at THIS case study on Target (TGT) You’ll see exactly how the tool works to trade long and short, even when the markets seem to be predicting the exact opposite. Now, this tool has been so accurate over recent months that I’m planning to send you 14 more real-world examples of winning trades that anyone using this tool could have captured. And it’s all building to Monday, February 24 @ 1pm ET when I’ll bring the tool to the public for the first time and show you how you can put it on your own charts!
Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc (FRX)
See More Fennec Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fennec Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fennec Pharmaceuticals and other key companies, straight to your email.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals (TSE:FRX) operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

View Fennec Pharmaceuticals Profile

More Earnings Resources from MarketBeat